Bloomberg News

Bridgepoint to Ask JPMorgan to Advise on Diaverum Future

January 21, 2013

Bridgepoint Advisers Ltd., a U.K. private-equity firm with more than $12 billion in committed funds, will choose JPMorgan Chase & Co. (JPM:US) to consider Swedish renal-care provider Diaverum’s future.

Bridgepoint “is close” to completing JPMorgan’s appointment to look at strategic options for Lund-based Diaverum for the next 12 months, James Murray, a spokesman for the firm, said by phone today.

Diaverum provides renal care to more than 20,000 patients at about 250 clinics in 17 countries, including in South America, Australia, Europe and the Middle East, according to information on its website. The company employs 6,900 people and reported sales of 398 million euros ($530 million) in 2011. Companies owned by London-based Bridgepoint employ 72,000 people in more than 40 countries, according to its website.

To contact the reporters on this story: Aaron Kirchfeld in London at akirchfeld@bloomberg.net; Niklas Magnusson in Stockholm at nmagnusson1@bloomberg.net

To contact the editor responsible for this story: Frank Connelly at fconnelly@bloomberg.net


We Almost Lost the Nasdaq
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • JPM
    (JPMorgan Chase & Co)
    • $59.0 USD
    • 0.33
    • 0.56%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus